Currently, several angiogenesis inhibitors that specifically target VEGF, VEGFR, or other specific genes that are involved in angiogenesis can prolong life expectancy in patients with advanced colon cancer and are now being investigated in clinical trials alone or in combination with conventional therapeutic approaches of both cancer and retinal disease (Hurwitz et al., 2004; Avery et al., 2006). The gene discussed is VEGFA; the disease is colonic neoplasm.